NO20034612L - 3,4-di-substituerte syklobuten-1,2-dioner, farmasoytiske preparater som omfatter forbindelsene, samt anvendelse av forbindelsene for tilvirkning av medikamenter for behandling av kjemokinformidlede sykdommer - Google Patents

3,4-di-substituerte syklobuten-1,2-dioner, farmasoytiske preparater som omfatter forbindelsene, samt anvendelse av forbindelsene for tilvirkning av medikamenter for behandling av kjemokinformidlede sykdommer

Info

Publication number: NO20034612L
Authority: NO; Norway
Prior art keywords: compounds; chemokine; dione; medicaments; manufacture
Prior art date: 2001-04-16

Application number

NO20034612A

Other languages

English (en)

Other versions

NO20034612D0 (no

NO330790B1 (no

Inventor

John J Baldwin

Arthur G Taveras

Jianping Chao

Johan A Ferreira

Cynthia J Aki

Richard W Bond

Michael Dwyer

J Robert Merritt

Laura L Rokosz

Jianhua Chao

Younong Yu

Bernd Kaiser

Ge Li

Kingsley H Nelson

Original Assignee

Pharmacopeia Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-16

Filing date

2003-10-15

Publication date

2003-12-08

2003-10-15 Application filed by Pharmacopeia Inc filed Critical Pharmacopeia Inc

2003-10-15 Publication of NO20034612D0 publication Critical patent/NO20034612D0/no

2003-12-08 Publication of NO20034612L publication Critical patent/NO20034612L/no

2011-07-18 Publication of NO330790B1 publication Critical patent/NO330790B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Neurosurgery (AREA)
Tropical Medicine & Parasitology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Biotechnology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
AIDS & HIV (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Hematology (AREA)
Psychiatry (AREA)

NO20034612A 2001-04-16 2003-10-15 3,4-di-substituerte syklobuten-1,2-dioner, farmasoytiske preparater som omfatter forbindelsene, samt anvendelse av forbindelsene for tilvirkning av medikamenter for behandling av kjemokinformidlede sykdommer NO330790B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US28402601P	2001-04-16	2001-04-16
PCT/US2002/012681 WO2002083624A1 (en)	2001-04-16	2002-04-15	3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands

Publications (3)

Publication Number	Publication Date
NO20034612D0 NO20034612D0 (no)	2003-10-15
NO20034612L true NO20034612L (no)	2003-12-08
NO330790B1 NO330790B1 (no)	2011-07-18

Family

ID=23088576

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20034612A NO330790B1 (no)	2001-04-16	2003-10-15	3,4-di-substituerte syklobuten-1,2-dioner, farmasoytiske preparater som omfatter forbindelsene, samt anvendelse av forbindelsene for tilvirkning av medikamenter for behandling av kjemokinformidlede sykdommer
NO20110050A NO20110050L (no)	2001-04-16	2011-01-12	3,4-disubstituerte syklobuten-1,2-dioner som CXC-kjemokinreseptorligander

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20110050A NO20110050L (no)	2001-04-16	2011-01-12	3,4-disubstituerte syklobuten-1,2-dioner som CXC-kjemokinreseptorligander

Country Status (31)

Country	Link
EP (2)	EP1381590B1 (no)
JP (3)	JP4499993B2 (no)
KR (2)	KR20100008794A (no)
CN (2)	CN1289471C (no)
AR (1)	AR035825A1 (no)
AT (2)	ATE458715T1 (no)
AU (3)	AU2002311841B2 (no)
BR (1)	BRPI0208957B8 (no)
CA (1)	CA2444031C (no)
CY (2)	CY1109908T1 (no)
CZ (1)	CZ20032831A3 (no)
DE (2)	DE60235507D1 (no)
DK (2)	DK1381590T3 (no)
EC (1)	ECSP034809A (no)
ES (2)	ES2287284T3 (no)
HK (2)	HK1057538A1 (no)
HU (1)	HUP0401783A3 (no)
IL (3)	IL158262A0 (no)
MX (1)	MXPA03009441A (no)
MY (2)	MY149050A (no)
NO (2)	NO330790B1 (no)
NZ (3)	NZ543869A (no)
PE (1)	PE20021084A1 (no)
PL (2)	PL207255B1 (no)
PT (2)	PT1818325E (no)
RU (1)	RU2344123C9 (no)
SI (2)	SI1818325T1 (no)
SK (1)	SK287598B6 (no)
TW (2)	TW200736196A (no)
WO (1)	WO2002083624A1 (no)
ZA (1)	ZA200307905B (no)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040106794A1 (en) *	2001-04-16	2004-06-03	Schering Corporation	3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US7132445B2 (en)	2001-04-16	2006-11-07	Schering Corporation	3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
MXPA04003439A (es)	2001-10-12	2004-07-08	Schering Corp	Compuestos de maleimida 3,4 disustituidos como antagonistas de receptor de quimiocina cxc.
US8246969B2 (en)	2001-11-16	2012-08-21	Skinmedica, Inc.	Compositions containing aromatic aldehydes and their use in treatments
US6878709B2 (en)	2002-01-04	2005-04-12	Schering Corporation	3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
NZ535314A (en)	2002-03-18	2007-08-31	Schering Corp	Combination treatments for chemokine-mediated diseases
GB0218326D0 (en) *	2002-08-07	2002-09-11	Glaxo Group Ltd	Compounds
JP4664074B2 (ja)	2002-10-09	2011-04-06	シェーリングコーポレイション	Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのチアジアゾールジオキシドおよびチアジアゾールオキシド
GB0302094D0 (en)	2003-01-29	2003-02-26	Pharmagene Lab Ltd	EP4 receptor antagonists
WO2004087153A2 (en) *	2003-03-28	2004-10-14	Chiron Corporation	Use of organic compounds for immunopotentiation
CA2521069C (en)	2003-04-03	2012-09-18	Merck Patent Gesellschaft Mit Beschraenkter Haftung	Pyrrolidino-1,2-dicarboxy-1-(phenylamide)-2-(4-(3-oxo-morpholino-4-yl)-phenylamide) derivatives and related compounds for use as inhibitors of coagulation factor xa in the treatment of thrombo-embolic diseases
ATE457307T1 (de) *	2003-04-18	2010-02-15	Schering Corp	Synthese von 2-hydroxy-n,n-dimethyl-3-[[2-[1(r)- (5-methyl-2-furanyl)propyl amino -3,4-dioxo-1- cyclobuten-1-yl amino benzamid
MXPA06000794A (es)	2003-07-22	2006-08-23	Astex Therapeutics Ltd	Compuestos 1h-pirazola 3,4-disustituida y su uso como moduladores de quinasas dependientes de ciclina (cdk) y quinasa-3 de sintasa de glicogeno (gsr-3).
GB0320983D0 (en) *	2003-09-08	2003-10-08	Biofocus Plc	Compound libraries
ES2335589T3 (es)	2003-09-23	2010-03-30	Fermion Oy	Preparacion de quetiapina.
GB0324269D0 (en)	2003-10-16	2003-11-19	Pharmagene Lab Ltd	EP4 receptor antagonists
WO2005066147A1 (en)	2003-12-19	2005-07-21	Schering Corporation	Thiadiazoles as cxc- and cc- chemokine receptor ligands
CA2550540A1 (en)	2003-12-22	2005-07-28	Schering Corporation	Isothiazole dioxides as cxc- and cc- chemokine receptor ligands
ATE478061T1 (de)	2004-01-30	2010-09-15	Schering Corp	Kristalline polymorphe eines cxc- chemokinrezeptorliganden
JP2007525521A (ja) *	2004-02-27	2007-09-06	シェーリング　コーポレイション	Ｃ型肝炎ウイルスｎｓ３セリンプロテアーゼのインヒビターとしてのシクロブテンジオン基含有化合物
EP1634573A1 (en) *	2004-08-16	2006-03-15	The Procter and Gamble Company	2-(Amino or substituted Amino)-5,6-substituted Phenol compounds, dyeing compositions containing them, and use thereof
WO2006023435A1 (en) *	2004-08-16	2006-03-02	The Procter & Gamble Company	2-(amino or substituted amino)-5, 6-substituted phenol compounds, dyeing compositions containing them, and use thereof
CA2580762A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as therapeutic agents
BRPI0515483A (pt)	2004-09-20	2008-07-22	Xenon Pharmaceuticals Inc	derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
AR051091A1 (es)	2004-09-20	2006-12-20	Xenon Pharmaceuticals Inc	Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
CN101083992A (zh)	2004-09-20	2007-12-05	泽农医药公司	抑制人硬脂酰CoA去饱和酶的哒嗪衍生物
JP2008513515A (ja)	2004-09-20	2008-05-01	ゼノン・ファーマシューティカルズ・インコーポレイテッド	複素環誘導体および治療薬としてのそれらの使用
AR051093A1 (es)	2004-09-20	2006-12-20	Xenon Pharmaceuticals Inc	Derivados heterociclicos y su uso como inhibidores de estearoil-coa desaturasa
CN101083994A (zh)	2004-09-20	2007-12-05	泽农医药公司	杂环衍生物及其用作硬脂酰CoA去饱和酶抑制剂的用途
ES2327840T3 (es)	2004-12-23	2009-11-04	Gpc Biotech Ag	Derivados de acido escuarico con actividad antiproliferativa.
US8404718B2 (en)	2005-01-21	2013-03-26	Astex Therapeutics Limited	Combinations of pyrazole kinase inhibitors
AR054425A1 (es)	2005-01-21	2007-06-27	Astex Therapeutics Ltd	Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
MX2007015216A (es)	2005-06-03	2008-02-22	Xenon Pharmaceuticals Inc	Derivados de aminotiazol y sus usos como agentes terapeuticos.
CN101253165A (zh)	2005-06-29	2008-08-27	先灵公司	作为cxc－化学活素受体配体的二取代的二唑
DE602006017849D1 (de) *	2005-06-29	2010-12-09	Schering Corp	5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc-chemokinrezeptors
DE102005035742A1 (de) *	2005-07-29	2007-02-01	Merck Patent Gmbh	Quadratsäurederivate II
PL1951663T3 (pl) *	2005-11-24	2017-01-31	Dompé Farmaceutici S.P.A.	Pochodne (R)-aryloalkiloaminowe i zawierające je kompozycje farmaceutyczne
JP5437061B2 (ja) *	2006-05-26	2014-03-12	アッヴィ・インコーポレイテッド	ポロ様キナーゼの阻害薬
TWI351399B (en) *	2006-06-12	2011-11-01	Schering Corp	Pharmaceutical formulations and compositions of a
CA2657051A1 (en) *	2006-07-07	2008-01-10	Schering Corporation	3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
US8450348B2 (en)	2007-02-21	2013-05-28	Forma Tm, Llc	Derivatives of squaric acid with anti-proliferative activity
WO2008148790A1 (en) *	2007-06-06	2008-12-11	Novartis Ag	Anti -inflammatory substituted cyclobutenedione compounds
CA2692269A1 (en) *	2007-07-03	2009-01-08	Schering Corporation	Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
RU2529468C2 (ru) *	2008-06-24	2014-09-27	Топотаргет А/С	Производные 1, 2-дигидроциклобутендиона в качестве ингибиторов фосфорибозилтрансферазы никотинамида
UA103198C2 (en)	2008-08-04	2013-09-25	Новартис Аг	Squaramide derivatives as cxcr2 antagonists
WO2010063802A1 (en) *	2008-12-05	2010-06-10	Novartis Ag	3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
MX2012013197A (es)	2010-05-12	2013-04-03	Abbvie Inc	Inhibidores de indazol de cinasa.
FR2961695B1 (fr)	2010-06-29	2012-07-06	Galderma Res & Dev	Utilisation de composes dans le traitement ou la prevention de troubles cutanes
SG10201602752XA (en)	2011-01-07	2016-05-30	Allergan Inc	Melanin modification compositions and methods of use
PT2760821T (pt)	2011-09-02	2018-01-11	Novartis Ag	Sal de colina de um composto anti-inflamatório de ciclobutenodiona substituída
FR2981934B1 (fr) *	2011-10-28	2013-12-20	Galderma Res & Dev	Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981936B1 (fr)	2011-10-28	2013-12-20	Galderma Res & Dev	Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981935B1 (fr) *	2011-10-28	2015-08-07	Galderma Res & Dev	Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
CN103242210B (zh) *	2012-02-09	2014-09-24	北京艾百诺科技有限公司	含有取代方酸的乙酸妙林酯及其应用
AR092809A1 (es)	2012-03-16	2015-05-06	Axikin Pharmaceuticals Inc	3,5-diaminopirazol como inhibidor de quinasa
US8889730B2 (en)	2012-04-10	2014-11-18	Pfizer Inc.	Indole and indazole compounds that activate AMPK
CN103382192A (zh) *	2012-05-04	2013-11-06	同创医药(苏州)有限公司	N-单取代哌嗪衍生物的制备
CA2905242C (en)	2013-03-15	2016-11-29	Pfizer Inc.	Indole compounds that activate ampk
CN103214327A (zh) *	2013-03-22	2013-07-24	郑州泰基鸿诺药物科技有限公司	一种芳香环或芳杂环三氟甲基酮化合物及其制备方法
US10561676B2 (en) *	2013-08-02	2020-02-18	Syntrix Biosystems Inc.	Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US10046002B2 (en)	2013-08-02	2018-08-14	Syntrix Biosystems Inc.	Method for treating cancer using chemokine antagonists
NZ631142A (en)	2013-09-18	2016-03-31	Axikin Pharmaceuticals Inc	Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
EA032473B1 (ru)	2014-12-23	2019-05-31	Аксикин Фармасьютикалз, Инк.	3,5-диаминопиразоловые ингибиторы киназы
FR3030515B1 (fr)	2014-12-23	2017-01-20	Galderma Res & Dev	Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines
TWI734715B (zh)	2015-11-19	2021-08-01	美商卡默森屈有限公司	趨化因子受體調節劑
TWI724056B (zh)	2015-11-19	2021-04-11	美商卡默森屈有限公司	Ｃｘｃｒ２抑制劑
WO2018073248A1 (en)	2016-10-17	2018-04-26	Icm (Institut Du Cerveau Et De La Moelle Épinière)	Prognosis of demyelinating diseases patients and treatment thereof
WO2019036374A1 (en) *	2017-08-14	2019-02-21	Allergan, Inc.	3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND THEIR USE
US11052065B2 (en)	2017-09-27	2021-07-06	Merck Sharp & Dohme Corp.	Compositions and methods for treating cancer with a combination of programmed death receptor (PD-1) antibodies and a CXCR2 antagonist
WO2019136370A2 (en)	2018-01-08	2019-07-11	Chemocentryx, Inc.	Methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2
UA128700C2 (uk)	2018-09-21	2024-10-02	Пфайзер Інк.	N-заміщені діоксоциклобутеніламіно-3-гідроксипіколінаміди, прийнятні як інгібітори ccr6
CN110041309B (zh) *	2019-04-04	2022-01-28	广东工业大学	一种2-羧基哌嗪连接的他克林-8-氨基(羟基)喹啉衍生物及制备与应用
JP2022551198A (ja) *	2019-10-07	2022-12-07	ディー．イー．ショウリサーチ，エルエルシー	Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリールメチレン複素環式化合物
KR102710925B1 (ko) *	2021-06-01	2024-09-27	부산대학교 산학협력단	신규 스퀘어아마이드 유도체 및 이의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0692915A (ja) *	1992-07-28	1994-04-05	Sumitomo Metal Ind Ltd	１，２−ジアミノシクロブテン−３，４−ジオン誘導体及びその用途
GB9312210D0 (en) *	1993-06-14	1993-07-28	Smithkline Beecham Plc	Chemical compounds
GB9316111D0 (en) *	1993-08-04	1993-09-22	Pfizer Ltd	Benzopyrans
US5354763A (en) *	1993-11-17	1994-10-11	American Home Products Corporation	Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
US5466712A (en) *	1994-11-04	1995-11-14	American Home Products Corporation	Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones
MX9703375A (es) *	1994-11-16	1997-08-30	American Home Prod	Diaminociclobuteno-3,4-dionas.
BR9709938A (pt) *	1996-06-27	1999-08-10	Smithkline Beecham Corp	Antagonistas dos receptores de il-8
US5840764A (en) *	1997-01-30	1998-11-24	American Home Products Corporation	Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
AU6250298A (en) *	1997-01-30	1998-08-25	American Home Products Corporation	Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
US6211220B1 (en) *	1998-11-23	2001-04-03	Cell Pathways, Inc.	Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives
CA2351464A1 (en) *	1998-12-14	2000-06-22	Joan E. Sabalski	3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by vla-4
ATE303359T1 (de) *	1998-12-16	2005-09-15		Biphenylverbindungen und biphenyl-analoge als intergrin-antagonisten
US6518283B1 (en) *	1999-05-28	2003-02-11	Celltech R&D Limited	Squaric acid derivatives
AR033803A1 (es) *	2000-03-01	2004-01-07	Smithkline Beecham Corp	Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas
CA2411323A1 (en) *	2000-05-30	2001-12-06	Michael R. Palovich	Il-8 receptor antagonists
US20040048897A1 (en) *	2001-01-16	2004-03-11	Mccleland Brent	Il-8 receptor antagonists
JP2005507366A (ja) *	2001-03-30	2005-03-17	スミスクライン・ビーチャム・コーポレイション	フェノール含有化合物の合成方法
NZ535314A (en) *	2002-03-18	2007-08-31	Schering Corp	Combination treatments for chemokine-mediated diseases

2002
- 2002-04-15 MY MYPI20070922A patent/MY149050A/en unknown
- 2002-04-15 KR KR1020097026265A patent/KR20100008794A/ko not_active Application Discontinuation
- 2002-04-15 NZ NZ543869A patent/NZ543869A/en not_active IP Right Cessation
- 2002-04-15 CN CNB028119797A patent/CN1289471C/zh not_active Expired - Fee Related
- 2002-04-15 PT PT07010711T patent/PT1818325E/pt unknown
- 2002-04-15 MY MYPI20021372A patent/MY138202A/en unknown
- 2002-04-15 ES ES02739172T patent/ES2287284T3/es not_active Expired - Lifetime
- 2002-04-15 CZ CZ20032831A patent/CZ20032831A3/cs unknown
- 2002-04-15 SI SI200230898T patent/SI1818325T1/sl unknown
- 2002-04-15 AR ARP020101371A patent/AR035825A1/es not_active Application Discontinuation
- 2002-04-15 PT PT02739172T patent/PT1381590E/pt unknown
- 2002-04-15 EP EP02739172A patent/EP1381590B1/en not_active Expired - Lifetime
- 2002-04-15 AT AT07010711T patent/ATE458715T1/de active
- 2002-04-15 HU HU0401783A patent/HUP0401783A3/hu unknown
- 2002-04-15 RU RU2003133448/04A patent/RU2344123C9/ru not_active IP Right Cessation
- 2002-04-15 AT AT02739172T patent/ATE365154T1/de active
- 2002-04-15 AU AU2002311841A patent/AU2002311841B2/en not_active Expired
- 2002-04-15 EP EP07010711A patent/EP1818325B1/en not_active Expired - Lifetime
- 2002-04-15 PL PL367129A patent/PL207255B1/pl unknown
- 2002-04-15 JP JP2002581381A patent/JP4499993B2/ja not_active Expired - Lifetime
- 2002-04-15 SI SI200230572T patent/SI1381590T1/sl unknown
- 2002-04-15 PL PL390082A patent/PL208928B1/pl unknown
- 2002-04-15 IL IL15826202A patent/IL158262A0/xx unknown
- 2002-04-15 WO PCT/US2002/012681 patent/WO2002083624A1/en active Application Filing
- 2002-04-15 NZ NZ529551A patent/NZ529551A/en not_active IP Right Cessation
- 2002-04-15 NZ NZ560453A patent/NZ560453A/en unknown
- 2002-04-15 DE DE60235507T patent/DE60235507D1/de not_active Expired - Lifetime
- 2002-04-15 BR BR0208957-2 patent/BRPI0208957B8/pt not_active IP Right Cessation
- 2002-04-15 DK DK02739172T patent/DK1381590T3/da active
- 2002-04-15 DE DE60220778T patent/DE60220778T2/de not_active Expired - Lifetime
- 2002-04-15 SK SK1288-2003A patent/SK287598B6/sk not_active IP Right Cessation
- 2002-04-15 MX MXPA03009441A patent/MXPA03009441A/es active IP Right Grant
- 2002-04-15 KR KR1020037013527A patent/KR100952531B1/ko not_active IP Right Cessation
- 2002-04-15 DK DK07010711.5T patent/DK1818325T3/da active
- 2002-04-15 ES ES07010711T patent/ES2340207T3/es not_active Expired - Lifetime
- 2002-04-15 CN CNA2006101374093A patent/CN1990457A/zh active Pending
- 2002-04-15 CA CA2444031A patent/CA2444031C/en not_active Expired - Lifetime
- 2002-04-16 PE PE2002000318A patent/PE20021084A1/es not_active Application Discontinuation
- 2002-04-16 TW TW096102669A patent/TW200736196A/zh unknown
- 2002-04-16 TW TW091107670A patent/TWI316930B/zh active
2003
- 2003-10-02 IL IL158262A patent/IL158262A/en not_active IP Right Cessation
- 2003-10-09 ZA ZA2003/07905A patent/ZA200307905B/en unknown
- 2003-10-15 NO NO20034612A patent/NO330790B1/no not_active IP Right Cessation
- 2003-10-16 EC EC2003004809A patent/ECSP034809A/es unknown
2004
- 2004-01-21 HK HK04100477A patent/HK1057538A1/xx not_active IP Right Cessation
2006
- 2006-08-24 AU AU2006203679A patent/AU2006203679A1/en not_active Abandoned
2007
- 2007-08-07 CY CY20071101059T patent/CY1109908T1/el unknown
2008
- 2008-02-13 HK HK08101594.0A patent/HK1107818A1/xx not_active IP Right Cessation
2009
- 2009-05-20 JP JP2009122594A patent/JP2009179641A/ja active Pending
- 2009-10-25 IL IL201754A patent/IL201754A0/en unknown
- 2009-12-08 JP JP2009278869A patent/JP5294418B2/ja not_active Expired - Lifetime
2010
- 2010-04-29 CY CY20101100380T patent/CY1109989T1/el unknown
- 2010-08-20 AU AU2010212484A patent/AU2010212484B2/en not_active Expired
2011
- 2011-01-12 NO NO20110050A patent/NO20110050L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AR035825A1 (es)	2004-07-14
PT1818325E (pt)	2010-05-12
RU2344123C2 (ru)	2009-01-20
IL158262A (en)	2012-05-31
ECSP034809A (es)	2004-02-26
JP5294418B2 (ja)	2013-09-18
MXPA03009441A (es)	2004-02-12
NO20034612D0 (no)	2003-10-15
AU2010212484A1 (en)	2010-09-09
TW200736196A (en)	2007-10-01
PL207255B1 (pl)	2010-11-30
AU2002311841B2 (en)	2006-09-14
EP1818325A2 (en)	2007-08-15
ES2340207T3 (es)	2010-05-31
ATE365154T1 (de)	2007-07-15
MY149050A (en)	2013-07-15
CA2444031C (en)	2012-02-21
DK1381590T3 (da)	2007-10-22
PL367129A1 (en)	2005-02-21
EP1818325A3 (en)	2008-02-13
JP4499993B2 (ja)	2010-07-14
HUP0401783A2 (hu)	2005-01-28
CA2444031A1 (en)	2002-10-24
BRPI0208957B8 (pt)	2021-05-25
HK1057538A1 (en)	2004-04-08
JP2009179641A (ja)	2009-08-13
NZ543869A (en)	2007-09-28
IL201754A0 (en)	2010-06-16
ZA200307905B (en)	2005-03-30
SK287598B6 (sk)	2011-03-04
JP2004532846A (ja)	2004-10-28
PT1381590E (pt)	2007-08-06
KR100952531B1 (ko)	2010-04-12
CN1289471C (zh)	2006-12-13
ATE458715T1 (de)	2010-03-15
NZ560453A (en)	2009-03-31
WO2002083624A1 (en)	2002-10-24
TWI316930B (en)	2009-11-11
CZ20032831A3 (cs)	2004-03-17
HUP0401783A3 (en)	2005-06-28
BRPI0208957B1 (pt)	2018-10-09
CN1990457A (zh)	2007-07-04
SK12882003A3 (sk)	2004-06-08
EP1381590B1 (en)	2007-06-20
SI1818325T1 (sl)	2010-06-30
SI1381590T1 (sl)	2007-10-31
KR20100008794A (ko)	2010-01-26
NO330790B1 (no)	2011-07-18
NZ529551A (en)	2006-02-24
DE60220778T2 (de)	2008-03-06
BR0208957A (pt)	2004-06-22
CY1109908T1 (el)	2014-09-10
DK1818325T3 (da)	2010-05-31
EP1381590A1 (en)	2004-01-21
RU2003133448A (ru)	2005-06-10
NO20110050L (no)	2003-12-08
MY138202A (en)	2009-05-29
DE60220778D1 (en)	2007-08-02
EP1818325B1 (en)	2010-02-24
CY1109989T1 (el)	2014-09-10
KR20030092074A (ko)	2003-12-03
PE20021084A1 (es)	2002-12-20
PL208928B1 (pl)	2011-06-30
JP2010053151A (ja)	2010-03-11
HK1107818A1 (en)	2008-04-18
IL158262A0 (en)	2004-05-12
DE60235507D1 (de)	2010-04-08
CN1516687A (zh)	2004-07-28
AU2010212484B2 (en)	2012-04-12
AU2006203679A1 (en)	2006-09-14
ES2287284T3 (es)	2007-12-16
RU2344123C9 (ru)	2009-05-20

Publication	Publication Date	Title
NO20034612L (no)	2003-12-08	3,4-di-substituerte syklobuten-1,2-dioner, farmasoytiske preparater som omfatter forbindelsene, samt anvendelse av forbindelsene for tilvirkning av medikamenter for behandling av kjemokinformidlede sykdommer
NO324227B1 (no)	2007-09-10	Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
NO20033594L (no)	2003-10-02	Fenetanolamin-derivater for behandling av luftveissykdommer
CY2014019I1 (el)	2015-12-09	Παραγωγα φαιναιθανολαμινης για θεραπεια ασθενειων του αναπνευστικου
NO20053077D0 (no)	2005-06-23	Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
NO20041277L (no)	2004-03-26	Farmasoytiske preparater for behandling av astma.
IT1318649B1 (it)	2003-08-27	Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
ATE478840T1 (de)	2010-09-15	3-aminoazetidinderivate enthaltende pharmazeutische zusammensetzungen, diese derivate und deren herstellung
NO20041452L (no)	2004-06-04	17-beta-hydroksysteroid-dehydrogenase type 3-inhibitorer for behandling av androgenavhengige sykdommer.
NO20032734D0 (no)	2003-06-16	Nye 1,2-difenylazetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder nevnte forbindelser og anvendelse avdisse for behandling av sykdommer fra lipidstoffskiftet
NO20043000L (no)	2004-07-13	Et preparat for behandling av nevrocerebrovaskulaere sykdommer
IL219397A0 (en)	2012-06-28	Compounds for the treatment of metabolic disorders, methods of preparing same, and pharmaceutical compositions containing same
NO20042739L (no)	2004-07-23	Farmasoytiske sammensetninger av 5,6,14-triazatetracyklo(10.3.1.0(2,11).0(4,9))-heksadeca-2(11)3,5,7,9-pentan
ITMI20011732A0 (it)	2001-08-07	Composizioni farmaceutiche e/o cosmetiche orali per il trattamento e la prevenzione di disturbi del cuoio capelluto
NO20033803D0 (no)	2003-08-26	Karbamat for behandling av bevegelseslidelser
HUP9900819A1 (hu)	2000-03-28	Biciklusos aromás vegyületek, alkalmazásuk a humán- és állatgyógyászatban és a kozmetikában
NO20035602D0 (no)	2003-12-16	Sammensetning som omfatter en PDE-4-inhibitor og H1- reseptorantagonist, samt anvendelse derav til fremstilling av et medikament forbehandling av åndedrettsykdommer
NO20025394D0 (no)	2002-11-11	Formuleringer inneholdende et glukokorticoid legemiddel for behandling av bronkopulmonire sykdommer
NO323466B1 (no)	2007-05-21	Nye kinolinyl-piperidin-4-yliden-metyl-benzamidderivater, fremgangsmate til fremstilling derav, anvendelse derav i medikamenter til behandling av smerte, samt farmasoytisk sammensetning som innbefatter slike derivater
ATE286894T1 (de)	2005-01-15	2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
SE9902937D0 (sv)	1999-08-18	Pharmaceutical compositions
NO20042476L (no)	2004-06-14	Anvendelse av desoxypeganin for behandling av klinisk depresjon
BR0211223A (pt)	2004-08-10	Derivados de 4-aminociclohexanol substituìdos
NO20003799D0 (no)	2000-07-25	Innkorporering av kolesterol-senkende midler i konfektdosisformer
EE200100527A (et)	2002-12-16	Osanetandi kasutamine meeleoluhäirete raviks kasulike ravimite valmistamiseks

Legal Events

Date	Code	Title	Description
2011-02-14	FC2A	Withdrawal, rejection or dismissal of laid open patent application
2011-04-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application
2012-09-24	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: MERCK SHARP AND DOHME CORP Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US
2015-11-23	MM1K	Lapsed by not paying the annual fees